Beta-Lactam Antibiotics InitiaL ExpoSure OptimisEd in CriticallY Ill Patients with SEpsis

ConditionsSepsis - to Reduce Mortality in the Intensive Care Unit Sepsis Septic Shock

Trial statusRecruiting

Trial phasePhase 4

Trial typeInterventional

Biological sexAll

Age18+

SponsorErasmus Medical Center

About this trial

The aim of this study is to investigate if an initial short double dose of beta-lactam antibiotics will reduce mortality in critically ill patients with sepsis.

Eligibility criteria

Qualifiers

≥18 years of age

Receiving intravenous antibiotic therapy of the target drugs (including continuous infusion of beta-lactam antibiotics)

Primary infection

Admitted to the ICU

Disqualifiers

Patient or legal representative not available to give informed consent within 72 hours after admittance

Pregnancy

Admittance for burn wounds

Patients receiving target antibiotics only as prophylaxis within the context of Selective Diges tive tract Decontamination (SDD)

Trial design

Treatments tested in this trial

Double dosing of beta-lactam antibiotic

Treatment groups

980 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Erasmus Medical Center

Lead sponsor

Maasstad Hospital

Collaborator

Albert Schweitzer Hospital

Collaborator

Source ClinicalTrials.gov